Sierra Leone President, Julius Maada Bio, has called for stronger regional cooperation and international support to tackle insecurity and poverty in West Africa as the Country marked its 16th Armed ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...

Bio-Rad Laboratories, Inc. BIO posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.51, which missed the Zacks Consensus Estimate by 2.3%. The bottom line decreased 13.4% from the ...

Bio-Rad develops products and solutions for the life sciences research and clinical diagnostic markets and enjoys niche market leadership in diagnostic quality controls, antigens, and digital ...

Unity (U) stock plunged 24% to $29.10 after Google DeepMind unveiled Genie 3 AI that generates interactive worlds from text. Unity CEO calls world model AI a powerful accelerator. Unity powers 70% of ...

Electric bike company Rad Power Bikes has reached a deal to sell itself to a company called Life Electric Vehicles Holdings (or Life EV) for around $13.2 million, a little more than a month after ...

Despite several indicators that Rad Power Bikes could be heading for closure soon, the brand announced the launch of a novel version of its cargo e-bike today, the “New RadWagon.” “Meet the New ...

Epic Games is teaming up with arguably its biggest game development rival. Epic Games is teaming up with arguably its biggest game development rival. is a senior reporter covering technology, gaming, ...

Precise Bio has reported the first successful human implantation of its 3D-printed cornea implant, constructed of functional human eye cells cultured in a laboratory. The company described the ...

Rad Power Bikes, one of the most well-known electric bicycle companies in North America, appears to be headed for collapse as troubling signs have continued to stack up. The Seattle, Washington-based ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...